THE CURELINE GROUP and Cellecta Inc LAUNCH TISSUE TO TARGET STRATEGIC PARTNERSHIP INITIATIVE
Brisbane, CA, and Mountain View, CA–(PRNewswire)–October XX, 2022
The Cureline Group and Cellecta, Inc. today announced the launch of Tissue to TargetTM a new strategic partnership to combine the companies’ core strengths in human biospecimen management and specialty lab services with a focus on immuno-oncology and auto-immune disease.
The Tissue to Target partnership will improve efficiency, cost and time to completion of early-phase clinical trials and translational medicine programs by leveraging the Cureline Group’s proven foundation in human biospecimen management with Cellecta’s renowned capabilities in functional genomics techniques for drug target and biomarker discovery and validation. Together, these two companies provide the highest level of expertise to facilitate evidence-based decision-making and superior clinical research outcomes.
“I am very excited about our new partnership with Cellecta. Cureline global capabilities in HBS management and Cellecta exceptional assay development expertise will provide new great opportunities to our clients working on human disease biomarker R&D”
Olga Potopova, Ph.D., CEO, CURELINE Group
“Cellecta is pleased to partner with the Cureline Group in enabling a streamlined workflow for translational medicine projects and early-stage clinical trials. With long-standing experience as a custom service provider of molecular and cell biology-based assays, including the DriverMap TM Adaptive Immune Repertoire Assay, Cellecta has enabled thousands of researchers in the pharmaceutical, biotechnology and academic sectors to achieve their discovery and development goals. Working with us, researchers benefit from synergies that will empower them to fast-track to successful outcomes.”
Alex Chenchik, Ph.D., Cellecta president and chief scientific officer
About The Cureline Group:
The Cureline Group has been providing human biospecimen and laboratory processing services for clinical trials since 2003. Its global clinical network and exceptional staff ensure efficient access to both standard and customized products for precision medicine and translational research, wherever you are in the world. Platform flexibility, cost-effectiveness and optimizing solutions: that’s the Cureline promise. (www.curelinegroup.com)
About Cellecta Inc.: